Arkolith/Insider Trading/OLMA/Form 4

Zojwalla Naseem

Chief Medical OfficerOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Dec 23, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.5M
Net Open-Market Flow
-$7.5M
Transactions
12
8 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 23, 2025Sell(S)100K$27.66$2.8M4K
Dec 23, 2025Option exercise(M)50K$7.02$351K104K
Dec 22, 2025Sell(S)100K$28.04$2.8M54K
Dec 22, 2025Option exercise(M)43K$15.25$653K147K
Dec 22, 2025Option exercise(M)7K$7.02$50K154K
Dec 19, 2025Option exercise(M)40K$15.25$610K174K
Dec 19, 2025Sell(S)57K$28.03$1.6M117K
Dec 19, 2025Sell(S)13K$28.93$374K104K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 23, 2025Option exercise(M)50K—$0157K
Dec 22, 2025Option exercise(M)7K—$0207K
Dec 22, 2025Option exercise(M)43K—$0112K
Dec 19, 2025Option exercise(M)40K—$0155K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001905871-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML